CA2045178C - Pressure-relieving device and process for implanting - Google Patents
Pressure-relieving device and process for implanting Download PDFInfo
- Publication number
- CA2045178C CA2045178C CA002045178A CA2045178A CA2045178C CA 2045178 C CA2045178 C CA 2045178C CA 002045178 A CA002045178 A CA 002045178A CA 2045178 A CA2045178 A CA 2045178A CA 2045178 C CA2045178 C CA 2045178C
- Authority
- CA
- Canada
- Prior art keywords
- body portion
- eye
- anterior chamber
- fluid
- sclera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Prostheses (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Steering Control In Accordance With Driving Conditions (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Fluid-Pressure Circuits (AREA)
- Eye Examination Apparatus (AREA)
Abstract
This invention involves a porous device (11) for implantation in the scleral tissue (12) of the eye to relieve the intraocular pressure of glaucoma and a method for surgically implanting the device (11).
The porous implant device (11) has an overall hex-ahedral shape and is surgically implanted within the scleral tissue (12) of the eye with at least one edge of the device at an open-ing (16) entering the anterior chamber (14), with no substantial extension into the anterior chamber (14) to provide efficient drain-age of aqueous fluid from the anterior chamber (14) for longer periods of time to provide intraocular pressure relief and prevent adverse effects of glaucoma.
The porous implant device (11) has an overall hex-ahedral shape and is surgically implanted within the scleral tissue (12) of the eye with at least one edge of the device at an open-ing (16) entering the anterior chamber (14), with no substantial extension into the anterior chamber (14) to provide efficient drain-age of aqueous fluid from the anterior chamber (14) for longer periods of time to provide intraocular pressure relief and prevent adverse effects of glaucoma.
Description
WO 91/07195 r f PCT/US90/06216 Pressure-relievincr Device and Process for Imr~lantinQ
Field of Invention This invention relates to the drainage of aqueous humour from eyes in the course of relieving eye disorders. Specifically, the invention relates to an implant which, when permanently affixed to or implanted in a specific area of the eye, will provide such drainage efficiently, for longer periods than heretofore accomplished, and, in short, will provide relief and prevent (or at least postpone) the adverse ultimate effects of glaucoma.
Background of the Invention The eyeball is composed of three basic layers: (1) the sclera, (2) the middle layer and (3) the retina.
The sclera is the outer layer of the eyeball.
It consists of tough, white tissue that serves as the supporting framework of the eye. At the front of the eye, the sclera is cantinuous with the clear, transparent cornea through which light enters the eve.
Behind the cornea is a small space, the anterior chamber, which contains a clear watery fluid called the aqueous humour.
The middle layer is composed of three parts:
(I) the choroid, (2) the ciliary muscle, and (3) the iris. The choroid lies behind and to the sides of the eyeball making up about 80% of the middle layer. It contains most of the blood vessels that nourish the eye.
Toward the, front of the eyeball, the choroid becomes the ciliary muscle. This muscle is connected WO 91 /0719; .~ :1.,~ ~ ,~ r~ _~
.~,~. ~,t; 1 ,. , ;_~
Field of Invention This invention relates to the drainage of aqueous humour from eyes in the course of relieving eye disorders. Specifically, the invention relates to an implant which, when permanently affixed to or implanted in a specific area of the eye, will provide such drainage efficiently, for longer periods than heretofore accomplished, and, in short, will provide relief and prevent (or at least postpone) the adverse ultimate effects of glaucoma.
Background of the Invention The eyeball is composed of three basic layers: (1) the sclera, (2) the middle layer and (3) the retina.
The sclera is the outer layer of the eyeball.
It consists of tough, white tissue that serves as the supporting framework of the eye. At the front of the eye, the sclera is cantinuous with the clear, transparent cornea through which light enters the eve.
Behind the cornea is a small space, the anterior chamber, which contains a clear watery fluid called the aqueous humour.
The middle layer is composed of three parts:
(I) the choroid, (2) the ciliary muscle, and (3) the iris. The choroid lies behind and to the sides of the eyeball making up about 80% of the middle layer. It contains most of the blood vessels that nourish the eye.
Toward the, front of the eyeball, the choroid becomes the ciliary muscle. This muscle is connected WO 91 /0719; .~ :1.,~ ~ ,~ r~ _~
.~,~. ~,t; 1 ,. , ;_~
2 _ by fibers to the lens, keeping the lens in place and controlling its shape. .
At the very front, the middle layer becomes the iris, a thin curtain of tissue in front of the lens. A round opening in the iris, whose size is controlled by muscles in the iris, is called the pupil.
In simple terms, the cornea refracts light through the anterior chamber and then through the pupil, the entrance aperture of the eye, to the lens.
The lens serves to focus the refracted light through the vitreous chamber containing the vitreous humour onto the retina, the rear surface of the eve.
Normally the fluid within the eye, the aqueous humour, is produced by the ciliary body and migrates through the pupil into the anterior chamber, the small space behind the cornea. From this chamber, the liquid migrates through the trabecular meshraork and into the aqueous veins which form fluid collection channels beneath the conjuctiva, the latter covering the front of the eyeball except for the cornea.
When the aqueous migration, described above, is insufficient to relieve the build-up of intra-ocular pressure, glaucoma results. This pressure build-up_ is usually due to one or more obstructions in the trabecular meshwork. Unless controlled, the high pressures associated with glaucoma ultimately leads to permanent damage of the optic nerve, the nerve formed from the sensitive fibers of the retina.
The object of the present invention is to provide a device that can be implanted permanently, simply and effectively to permit substantially normal migration of fluid out of the anterior chamber of the eye and, thus, avoid the abnormal build-up of intra-ocular pressure. Another ob-iect- ;~ +-~ ,...A..;~_ the implant in a manner that will also avoid excessive WO 91/07195 r, ~ r PCT/US90/06216 ~~~~r~:~~..1~
At the very front, the middle layer becomes the iris, a thin curtain of tissue in front of the lens. A round opening in the iris, whose size is controlled by muscles in the iris, is called the pupil.
In simple terms, the cornea refracts light through the anterior chamber and then through the pupil, the entrance aperture of the eye, to the lens.
The lens serves to focus the refracted light through the vitreous chamber containing the vitreous humour onto the retina, the rear surface of the eve.
Normally the fluid within the eye, the aqueous humour, is produced by the ciliary body and migrates through the pupil into the anterior chamber, the small space behind the cornea. From this chamber, the liquid migrates through the trabecular meshraork and into the aqueous veins which form fluid collection channels beneath the conjuctiva, the latter covering the front of the eyeball except for the cornea.
When the aqueous migration, described above, is insufficient to relieve the build-up of intra-ocular pressure, glaucoma results. This pressure build-up_ is usually due to one or more obstructions in the trabecular meshwork. Unless controlled, the high pressures associated with glaucoma ultimately leads to permanent damage of the optic nerve, the nerve formed from the sensitive fibers of the retina.
The object of the present invention is to provide a device that can be implanted permanently, simply and effectively to permit substantially normal migration of fluid out of the anterior chamber of the eye and, thus, avoid the abnormal build-up of intra-ocular pressure. Another ob-iect- ;~ +-~ ,...A..;~_ the implant in a manner that will also avoid excessive WO 91/07195 r, ~ r PCT/US90/06216 ~~~~r~:~~..1~
- 3 _ migration of fluid that would lead to collapse of the anterior chamber with its accompanying complications.
Prior Art U..S. Patent 4.457 757, issued July 3, 1984 to A.C.B. Molteno, involves the use of at least two ridged bodies anchored to the sclera with two tubular extensions, one communicating through the sclera to the anterior chamber to drain the aqueous humour out of the ZO eyeball.
U. S. Patent 4 750 901, issued June 14, 1988, to A.C.B. Molteno, recognized a problem that arose with his earlier device (as described in U.S. Patent 4,457,757). In the first few days after insertion of the earlier device, the pressure within the eye tends to fall to an unacceptably low level "which may result in surgical complications which damage sight". This fall in pressure is due to excessive absorption of the aqueous humour by the patient's Tenon capsule, a smooth layer of.tissue that covers the scleral plate when it is sutured to the eye. This later patent discloses the use of a subsidiary ridge in the upper surface the scleral plate that provides, with a portion of the ' Tenon's tissue, a small cavity where aqueous humour is drained initially and, thus, the aqueous humour can only be partially absorbed by the small area of Tenon's tissue exposed.
U.S. Patent 4.634 418, issued January 6, 1987, to P.S. Binder, involves the implantation of a seton constructed of a hydrogel in the anterior chamber of the eye to alleviate intra-ocular pressure. Once implanted, the seton acts as a wick to transfer aaueous humour from the anterior chamber to the space under the conjunctiva without allowing bacteria to ingress into the eye. Implantation is made after the removal of a WO 91 /0719; ~ r~ ;~ '.7 ,'._ ~-~ b PCT/US90/06216 ..
rectangular-sized piece of cornea, Schalbe's line and a portion of the trabecular meshwork.
U.S. Patent 4 722 724, issued February 2, 1988, to S. Schocket, involves the use of an implant that includes two connected tubes or a tube connected to a band. One tube is located in the anterior chamber and the other tube or band is located around the orbit of the eye. To prevent hypotony, a destructible value is located at the end of the tube inserted with the interior chamber to control the pressure of the aqueous humour flowing from the chamber.
U.S. Patent 4 787 885, issued November 29, 1988 to P.S. Binder, is a continuation of an application that was a continuation-in-par of the application that resulted in U.S. Patent 4,634,418.
This patent, like its predecessor, also involves the removal of a rectangular-sized piece of cornea, Schwalbe's line and a portion of the trabecular meshwork to accomodate a seton; and the seton permits migration of the aqueous humour from the anterior chamber to the area beneath the conjunctiva (the external covering of the eye).
In both patents, the inventor achieves fluid flow to the exterior of the sclera into a space created beneath the conjunctiva and the accompanying Tenon's tissue that covers the scleral plate, i.e. outside the main body of the eye. Since these areas are particularly agressive in healing, the reduction in ' intra-ocular pressure is short-lived; the space created beneath the conjunctiva and the tenon tissue tends to collapse and prevent further migration of the fluid from the anterior chamber with the consequent pressure increase, characteristic of glaucoma.
The object of the present invention is to provide a means and method for treating the excessive WO 91/0719a PCf/US90/0621b l~ :J ''~ ~ ~ r~
Prior Art U..S. Patent 4.457 757, issued July 3, 1984 to A.C.B. Molteno, involves the use of at least two ridged bodies anchored to the sclera with two tubular extensions, one communicating through the sclera to the anterior chamber to drain the aqueous humour out of the ZO eyeball.
U. S. Patent 4 750 901, issued June 14, 1988, to A.C.B. Molteno, recognized a problem that arose with his earlier device (as described in U.S. Patent 4,457,757). In the first few days after insertion of the earlier device, the pressure within the eye tends to fall to an unacceptably low level "which may result in surgical complications which damage sight". This fall in pressure is due to excessive absorption of the aqueous humour by the patient's Tenon capsule, a smooth layer of.tissue that covers the scleral plate when it is sutured to the eye. This later patent discloses the use of a subsidiary ridge in the upper surface the scleral plate that provides, with a portion of the ' Tenon's tissue, a small cavity where aqueous humour is drained initially and, thus, the aqueous humour can only be partially absorbed by the small area of Tenon's tissue exposed.
U.S. Patent 4.634 418, issued January 6, 1987, to P.S. Binder, involves the implantation of a seton constructed of a hydrogel in the anterior chamber of the eye to alleviate intra-ocular pressure. Once implanted, the seton acts as a wick to transfer aaueous humour from the anterior chamber to the space under the conjunctiva without allowing bacteria to ingress into the eye. Implantation is made after the removal of a WO 91 /0719; ~ r~ ;~ '.7 ,'._ ~-~ b PCT/US90/06216 ..
rectangular-sized piece of cornea, Schalbe's line and a portion of the trabecular meshwork.
U.S. Patent 4 722 724, issued February 2, 1988, to S. Schocket, involves the use of an implant that includes two connected tubes or a tube connected to a band. One tube is located in the anterior chamber and the other tube or band is located around the orbit of the eye. To prevent hypotony, a destructible value is located at the end of the tube inserted with the interior chamber to control the pressure of the aqueous humour flowing from the chamber.
U.S. Patent 4 787 885, issued November 29, 1988 to P.S. Binder, is a continuation of an application that was a continuation-in-par of the application that resulted in U.S. Patent 4,634,418.
This patent, like its predecessor, also involves the removal of a rectangular-sized piece of cornea, Schwalbe's line and a portion of the trabecular meshwork to accomodate a seton; and the seton permits migration of the aqueous humour from the anterior chamber to the area beneath the conjunctiva (the external covering of the eye).
In both patents, the inventor achieves fluid flow to the exterior of the sclera into a space created beneath the conjunctiva and the accompanying Tenon's tissue that covers the scleral plate, i.e. outside the main body of the eye. Since these areas are particularly agressive in healing, the reduction in ' intra-ocular pressure is short-lived; the space created beneath the conjunctiva and the tenon tissue tends to collapse and prevent further migration of the fluid from the anterior chamber with the consequent pressure increase, characteristic of glaucoma.
The object of the present invention is to provide a means and method for treating the excessive WO 91/0719a PCf/US90/0621b l~ :J ''~ ~ ~ r~
intra-ocular pressure characteristic of glaucoma in a manner which will not be defeated by the subsea_uent healing process i.e. in a manner that will provide the patient with relief for several years. A further object is to help avoid other problems such as collan_se of the anterior chamber, penetration of scar tissue over the trabecular meshwork, which tend to occur in the immediate post operative period with the conventional glaucoma surgery (trabeculotomy) disclosed in the prior art.
Summary of the Invention The invention involves an implant taa~ is biocompatible with the tissue of the eye and allows fluid to migrate from the anterior chamber into the coarsely woven fibers of the sclera, thus by-passing the obstructed trabecular meshwork but, instead o~
leaving the body of the eye, exiting into the outer layer of the eyball, the sclera. The normal pressure of fluid in the sclera serves to control the flow from the anterior chamber in a way that disastrous collabse of the chamber is prevented. Further, by not creating a space to accept fluid beneath the conjunctiva anc =he associated Tenon's tissue, the aggressive healing of these areas is not effective in re-creating the excessive intra-ocular pressure in the anterior chamber.
Basically, this invention involves substituting a material that is composed of small pores of similar size or larger than a healthy trabecular meshwork in an area almost adjacent to the area of the troubled trabecular meshwor., i.e. close to where the sclera meets the cornea. In this manner, an area of relatively small pores within the implant, is placed within the relatively large pores of the sclera.
Specifically, the device for relieving intraoeular pressure comprises a body portion and wall portions in substantially hexahedral form; at least the body portion is composed of a biocompatible porous S hydrogel material. The device is adapted to be implanted within the scleral tissue of the eye with at least one edge of the device at an opening of, with no substantial extension into, the anterior chamber adjacent to the area where the sclera makes the transition into the clear cornea of the eye. The pores of the body portion are of such size and auantity as to permit drainage of fluid from the anterior chamber to the,scleral tissue without collapse of the anterior chamber. The wall portions have at least one extension 1~ on at least one wall portion for anchoring the device securely in position.
The implant is made from a hydrogel or other material which is biocompatible with the tissue of the eye. Such hydrogel material may have a water content ranging anywhere from about 30% to about 800.
Typically, such materials comprise silicones, acrylic polymers and/or fluorocarbon polymers or the like. The implant is shaped to retain its position once it is implanted within the eye and to provide sufficient surface area to accomodate the migration of the aaueou humour in a controlled manner, i.e. enough migration to .
reduce intra~-ocular pressure but not enough to cause collapse of the chamber.
The invention will be more clearly understood by referring to the drawings and the description which follow.
PCT'/US90/06216 WO 91 /07196 ~ ~ '~i ~ ~ ,'~ U
The Drawincrs Figure 1 is a cross--sectional view of the eye showing one embodiment of the invention implanted therein;
Figure 2 is a side view of that embodiment of the invention;
Figure 3 is a front view of that embodiment;
Figure 4 is a plan or top view of that emobodiment;
Figure 5 is a side view of another emobodiment of the invention;
Figure 6 is a front view of that other embodiment; and Figure 7 is a plan view of Thai other embodiment.
Detailed Description of the Invention In the first embodiment, the overall shape of the device 11 is a hexahedral structure having a substantially rectangular cross-section as shown in Figure 1, approximately 6 mm in length, 3 mm in width, and 1/2 mm in depth. The device i1 is designed to be placed in a pocket made in the sclera 12 as seen in Figure 1 in the following manner. An incision is made in the sclera, 2 mm from the limbus of the eye. A
rectangular flap is raised into the clear cornea _13.
The overall thickness of this flap is approximately 1/3 mm. Following the same incision technique, another flap of sclera 12 is raised underneath the previously made flap but extending into clear cornea 13. This block of sclera is then excised by entering the anterior chamber 14 at the anterior wound edge 1~ (just as the sclera 12 makes the transition into clear cornea, 13). The aqueous fluid would then be able to enter this space through an opening 16, 41/2 mm ~,i '.>
in length, 1 mm in width, and 1/2 mm in depth. (Since the cornea follows a curve, the tissue excised would be triangular when viewed from the side.) The implant 11 is then placed in this pocket created in the sclera 12 with the anterior portion of the device anchored in the lamellar shelf 17 previously created in the clear cornea 13. It should be noted that by anchoring the device in the lamellar shelf rather than extending the device into the anterior chamber, contact with the endothelial cells 18 along the interior surface of the cornea is avoided. Such contact would result in the death of these cells and the loss of corneal function.
Small lamellar dissections (lmm in size) are created in the posterior wall, medial wall and lateral wall of the sclera 12. Using the embodiment of the device containing flanges, the flanges 19 (or extensions integral with the device) are placed within these lamellar dissections. By sliding the device 11 , anteriorly, it becomes firmly anchored in the previously prepared corneal lamellar shelf 17. If necessary, it can be-further secured by suturing the device to assure maintenance of its position. The first scleral flap is then sutured back into position.
The sclera 12 with the implant 11 in position would be of approximately the same thickness as before the procedure.
Fluid would then exit the anterior chamber 14 through the incision under the flap and to the implanted device 11: It would then enter the implant 11 which would allow it access to three.ver~ical walls of sclera because of the porous nature of the interior 20 of the implant. The coarsely woven fibers of the vertically cut sclera 12 would then allow the fluid to exit into the tissue 21 of the sclera 12.
:~tJB~TI'P'~JT~ SHE~'~°
WO 91 /0719; PCT/US90/06216 The other embodiment shown in Figures 5, 6 and 7 consists of a similar basic implant 11. having similar dimensions but with a thin flange 19 (1/8 mm) around the base of the implant on all four sides. The flange would project 1 mm from the sides that would be in contact with the sclera only and about 1/2 mm for the side which would project into a raised flange.
This raised flange is attached by a 1 mm extension 22 of the vertical walls of the portion of the implant in contact with the sclera. This extension is approximately 1/8 mm thick. Attached perpendicularly to this extension is the flange 19. The point of attachment is at the mid section of the flange. The flange is 1/8 mm thick and 2 mm wide. The posterior section is 7 mm in length and the two sides are 2 1/2 mm in length.
This embodiment is implanted in a similar fashion to the previously described implant with the following modifications. 1. The initial scleral flap would be 1/2 mm. 2. A block of sclera would not be excised. 3. A lamellar dissection would be performed at the base of the flap for approximately 1 mm. 4.
After the opening into the anterior chamber is created, the implant is placed into position sliding the 2,5 posterior flange into the previously formed space from the lamellar dissection. The scleral flan is then placed back into its previous position and underneath the superior flange. This superior flange would overlie the incision into the sclera to create a flan of 1 mm on each side except for the furthermost anterior aspect (which would not be covered by Tenon's tissue since it does not insert as fa~° anteriorly as the conjunctiva). The scleral flap is then sutured into position through the superior flange.
This embodiment would help prevent ingrowth of Tenon's tissue into the incision and would be firmly WO 91107196 ~ ~ r ~ ~~ ~ PCT/US90/06216 ,, t~ :~ .~ ~
- to -anchored into position. It also would allow access to vertically cut edges of sclera in the same manner as the previous embodiment.
' A further modification of the device of the invention involves the particular method by which the fluid from the anterior chamber travels to the sclera.
This modification would involve the use of a meshwork of fibers to allow rapid flow of fluid through the spaces between the fibers. The meshwork of fibers being made of a biocompatible material would be flexible. The meshwork would allow fluid flow to the vertically cut edges of the implant and the sclera.
Another way to achieve porosity would be through a system of channels through the implant. A
variety of patterns could be cut so as to achieve high fluid flow through the implant to the vertically cut edges. For example, a fan shaped system of drilled holes or a grid pattern of drilled holes from front to back or an interlocking pattern drilled from side to side, etc. could be used. The purpose and design are such that fluid could pass through, as described above, and the implant would resist collapse from the imposed pressure.
A typical operation for inserting the preferred embodiment of the invention follows: After retrobulbar anesthesia, the superior rectus muscle is placed on a four o silk bridal suture. Following this, a conjunctival flap is raised starting at the superior rectus and working fonaard to the limbus. This is then reflected.back to the cornea. Cantery is used to obtain hemostasis and to outline the location of the placement for the implant. A rectangular area, 5 mm by 3 mm, is outlined using a 64 Beaver blade. A small groove is made on the sclera side to half the depth of the sclera. This is grasped at one corner and the flap W0,91/07195 ~ ~ ..y c~ ~ ~ ~ PCf/US90/06216 .. ; l~
is dissected anteriorly,until the rectangular flap is completely raised in the clear cornea. At this point a 75 blade is used to make a stab incision into the anterior chamber of the eye and a 1 by 4 mm section of the cornea and trabecular meshwork are excised en bloc.
Using a lamellar dissecting blade, attention is turned to the posterior aspect of the bed of the rectangular flap. Further dissection at the base is carried posteriorly for approximately o.5 millimeter.
The implant is then placed into position in this bed with the inferior posterior flap laid into the groove that has just been created on the posterior aspect of the bed. The anterior portion is in direct communication with the anterior chamber. The scleral flap is then laid over this implant and tucked in underneath the superior flanges that are present, If necessary, a portion of the scleral flap can be excised so that the sclera lays down smoothly over the implant.
The implant is then sutured to the sclera on both sides with a 10-O nylon suture through the fixation holes in the superior flange. The conjunctival tissue is then sutured back together with a 6-0-plain gut running suture.
Summary of the Invention The invention involves an implant taa~ is biocompatible with the tissue of the eye and allows fluid to migrate from the anterior chamber into the coarsely woven fibers of the sclera, thus by-passing the obstructed trabecular meshwork but, instead o~
leaving the body of the eye, exiting into the outer layer of the eyball, the sclera. The normal pressure of fluid in the sclera serves to control the flow from the anterior chamber in a way that disastrous collabse of the chamber is prevented. Further, by not creating a space to accept fluid beneath the conjunctiva anc =he associated Tenon's tissue, the aggressive healing of these areas is not effective in re-creating the excessive intra-ocular pressure in the anterior chamber.
Basically, this invention involves substituting a material that is composed of small pores of similar size or larger than a healthy trabecular meshwork in an area almost adjacent to the area of the troubled trabecular meshwor., i.e. close to where the sclera meets the cornea. In this manner, an area of relatively small pores within the implant, is placed within the relatively large pores of the sclera.
Specifically, the device for relieving intraoeular pressure comprises a body portion and wall portions in substantially hexahedral form; at least the body portion is composed of a biocompatible porous S hydrogel material. The device is adapted to be implanted within the scleral tissue of the eye with at least one edge of the device at an opening of, with no substantial extension into, the anterior chamber adjacent to the area where the sclera makes the transition into the clear cornea of the eye. The pores of the body portion are of such size and auantity as to permit drainage of fluid from the anterior chamber to the,scleral tissue without collapse of the anterior chamber. The wall portions have at least one extension 1~ on at least one wall portion for anchoring the device securely in position.
The implant is made from a hydrogel or other material which is biocompatible with the tissue of the eye. Such hydrogel material may have a water content ranging anywhere from about 30% to about 800.
Typically, such materials comprise silicones, acrylic polymers and/or fluorocarbon polymers or the like. The implant is shaped to retain its position once it is implanted within the eye and to provide sufficient surface area to accomodate the migration of the aaueou humour in a controlled manner, i.e. enough migration to .
reduce intra~-ocular pressure but not enough to cause collapse of the chamber.
The invention will be more clearly understood by referring to the drawings and the description which follow.
PCT'/US90/06216 WO 91 /07196 ~ ~ '~i ~ ~ ,'~ U
The Drawincrs Figure 1 is a cross--sectional view of the eye showing one embodiment of the invention implanted therein;
Figure 2 is a side view of that embodiment of the invention;
Figure 3 is a front view of that embodiment;
Figure 4 is a plan or top view of that emobodiment;
Figure 5 is a side view of another emobodiment of the invention;
Figure 6 is a front view of that other embodiment; and Figure 7 is a plan view of Thai other embodiment.
Detailed Description of the Invention In the first embodiment, the overall shape of the device 11 is a hexahedral structure having a substantially rectangular cross-section as shown in Figure 1, approximately 6 mm in length, 3 mm in width, and 1/2 mm in depth. The device i1 is designed to be placed in a pocket made in the sclera 12 as seen in Figure 1 in the following manner. An incision is made in the sclera, 2 mm from the limbus of the eye. A
rectangular flap is raised into the clear cornea _13.
The overall thickness of this flap is approximately 1/3 mm. Following the same incision technique, another flap of sclera 12 is raised underneath the previously made flap but extending into clear cornea 13. This block of sclera is then excised by entering the anterior chamber 14 at the anterior wound edge 1~ (just as the sclera 12 makes the transition into clear cornea, 13). The aqueous fluid would then be able to enter this space through an opening 16, 41/2 mm ~,i '.>
in length, 1 mm in width, and 1/2 mm in depth. (Since the cornea follows a curve, the tissue excised would be triangular when viewed from the side.) The implant 11 is then placed in this pocket created in the sclera 12 with the anterior portion of the device anchored in the lamellar shelf 17 previously created in the clear cornea 13. It should be noted that by anchoring the device in the lamellar shelf rather than extending the device into the anterior chamber, contact with the endothelial cells 18 along the interior surface of the cornea is avoided. Such contact would result in the death of these cells and the loss of corneal function.
Small lamellar dissections (lmm in size) are created in the posterior wall, medial wall and lateral wall of the sclera 12. Using the embodiment of the device containing flanges, the flanges 19 (or extensions integral with the device) are placed within these lamellar dissections. By sliding the device 11 , anteriorly, it becomes firmly anchored in the previously prepared corneal lamellar shelf 17. If necessary, it can be-further secured by suturing the device to assure maintenance of its position. The first scleral flap is then sutured back into position.
The sclera 12 with the implant 11 in position would be of approximately the same thickness as before the procedure.
Fluid would then exit the anterior chamber 14 through the incision under the flap and to the implanted device 11: It would then enter the implant 11 which would allow it access to three.ver~ical walls of sclera because of the porous nature of the interior 20 of the implant. The coarsely woven fibers of the vertically cut sclera 12 would then allow the fluid to exit into the tissue 21 of the sclera 12.
:~tJB~TI'P'~JT~ SHE~'~°
WO 91 /0719; PCT/US90/06216 The other embodiment shown in Figures 5, 6 and 7 consists of a similar basic implant 11. having similar dimensions but with a thin flange 19 (1/8 mm) around the base of the implant on all four sides. The flange would project 1 mm from the sides that would be in contact with the sclera only and about 1/2 mm for the side which would project into a raised flange.
This raised flange is attached by a 1 mm extension 22 of the vertical walls of the portion of the implant in contact with the sclera. This extension is approximately 1/8 mm thick. Attached perpendicularly to this extension is the flange 19. The point of attachment is at the mid section of the flange. The flange is 1/8 mm thick and 2 mm wide. The posterior section is 7 mm in length and the two sides are 2 1/2 mm in length.
This embodiment is implanted in a similar fashion to the previously described implant with the following modifications. 1. The initial scleral flap would be 1/2 mm. 2. A block of sclera would not be excised. 3. A lamellar dissection would be performed at the base of the flap for approximately 1 mm. 4.
After the opening into the anterior chamber is created, the implant is placed into position sliding the 2,5 posterior flange into the previously formed space from the lamellar dissection. The scleral flan is then placed back into its previous position and underneath the superior flange. This superior flange would overlie the incision into the sclera to create a flan of 1 mm on each side except for the furthermost anterior aspect (which would not be covered by Tenon's tissue since it does not insert as fa~° anteriorly as the conjunctiva). The scleral flap is then sutured into position through the superior flange.
This embodiment would help prevent ingrowth of Tenon's tissue into the incision and would be firmly WO 91107196 ~ ~ r ~ ~~ ~ PCT/US90/06216 ,, t~ :~ .~ ~
- to -anchored into position. It also would allow access to vertically cut edges of sclera in the same manner as the previous embodiment.
' A further modification of the device of the invention involves the particular method by which the fluid from the anterior chamber travels to the sclera.
This modification would involve the use of a meshwork of fibers to allow rapid flow of fluid through the spaces between the fibers. The meshwork of fibers being made of a biocompatible material would be flexible. The meshwork would allow fluid flow to the vertically cut edges of the implant and the sclera.
Another way to achieve porosity would be through a system of channels through the implant. A
variety of patterns could be cut so as to achieve high fluid flow through the implant to the vertically cut edges. For example, a fan shaped system of drilled holes or a grid pattern of drilled holes from front to back or an interlocking pattern drilled from side to side, etc. could be used. The purpose and design are such that fluid could pass through, as described above, and the implant would resist collapse from the imposed pressure.
A typical operation for inserting the preferred embodiment of the invention follows: After retrobulbar anesthesia, the superior rectus muscle is placed on a four o silk bridal suture. Following this, a conjunctival flap is raised starting at the superior rectus and working fonaard to the limbus. This is then reflected.back to the cornea. Cantery is used to obtain hemostasis and to outline the location of the placement for the implant. A rectangular area, 5 mm by 3 mm, is outlined using a 64 Beaver blade. A small groove is made on the sclera side to half the depth of the sclera. This is grasped at one corner and the flap W0,91/07195 ~ ~ ..y c~ ~ ~ ~ PCf/US90/06216 .. ; l~
is dissected anteriorly,until the rectangular flap is completely raised in the clear cornea. At this point a 75 blade is used to make a stab incision into the anterior chamber of the eye and a 1 by 4 mm section of the cornea and trabecular meshwork are excised en bloc.
Using a lamellar dissecting blade, attention is turned to the posterior aspect of the bed of the rectangular flap. Further dissection at the base is carried posteriorly for approximately o.5 millimeter.
The implant is then placed into position in this bed with the inferior posterior flap laid into the groove that has just been created on the posterior aspect of the bed. The anterior portion is in direct communication with the anterior chamber. The scleral flap is then laid over this implant and tucked in underneath the superior flanges that are present, If necessary, a portion of the scleral flap can be excised so that the sclera lays down smoothly over the implant.
The implant is then sutured to the sclera on both sides with a 10-O nylon suture through the fixation holes in the superior flange. The conjunctival tissue is then sutured back together with a 6-0-plain gut running suture.
Claims (8)
1. A device for relieving intraocular pressure comprises a body portion and wall portion in the form of a hexahedron, at least the body portion composed of a biocompatible,porous material; said device adapted to be implanted within the scleral tissue of the eye with at least one edge of the device at an opening of, with no substantial extension into, the anterior chamber and adjacent to the area where the sclera makes the transition into clear cornea of the eye; the pores of the body portion are of such size and quantity as to permit drainage of fluid from the anterior chamber to the scleral tissue without collapse of the anterior chamber.
2. A device for relieving intraocular pressure comprising a body portion constructed of a biocompatible material having flow passages selected from the group consisting of pores, openings and channels therethrough; said device adapted to be implanted within the scleral tissue of the eye to allow fluid to pass through said flow passages from a first portion of the device at an area adjacent an opening of, with no substantial extension into, the anterior chamber of the eye at a position adjacent to the area of the eye where the sclera makes the transition into clear cornea of the eye; to a second portion within the scleral tissue of the eye, the space between said first and second portions defining the dimension of the body portion through which fluid can flow; said flow passages are of such size and quantity as to permit drainage of fluid from the anterior chamber to the scleral tissue without collapse of the anterior chamber.
3. A device as in claim 2 wherein the body portion comprises a meshwork of fibers disposed within said body portion, said meshwork of fibers being constructed to allow flow of fluid through a plurality of spaces defined between fibers of said meshwork of fibers from said first portion through said body portion to said second portion of said body portion.
4. A device as in claim 2 wherein the body portion includes a plurality of channels provided therethrough, said plurality of channels being configured to allow fluid to flow from said first portion of said body portion to said second portion of said body portion through said plurality of channels.
5. A device as in claim 2 wherein the body portion includes a plurality of fan shaped channels provided therethrough, said plurality of fan shaped channels being constructed to allow fluid to flow from said first portion of said body portion to said second portion of said body portion.
6. A device as in claim 2 wherein said body portion is porous, whereby fluid can flow from said first portion of said body portion to said second portion of said body portion through pores defined within said body portion.
7. A device as in claim 2 wherein said body portion has at least one surface, said surface having at least one edge extending therefrom for anchoring the device in position.
8. A use of the device of claim 1 or 2 for reducing intraocular pressure in a patient in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/437,840 US4946436A (en) | 1989-11-17 | 1989-11-17 | Pressure-relieving device and process for implanting |
US437,840 | 1989-11-17 | ||
PCT/US1990/006216 WO1991007195A1 (en) | 1989-11-17 | 1990-10-26 | Pressure-relieving device and process for implanting |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2045178A1 CA2045178A1 (en) | 1991-05-18 |
CA2045178C true CA2045178C (en) | 2002-12-31 |
Family
ID=23738124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002045178A Expired - Fee Related CA2045178C (en) | 1989-11-17 | 1990-10-26 | Pressure-relieving device and process for implanting |
Country Status (15)
Country | Link |
---|---|
US (1) | US4946436A (en) |
EP (1) | EP0454838B1 (en) |
JP (1) | JP3044238B2 (en) |
KR (1) | KR100187526B1 (en) |
CN (1) | CN1026754C (en) |
AT (1) | ATE115388T1 (en) |
CA (1) | CA2045178C (en) |
DE (1) | DE69015161T2 (en) |
DK (1) | DK0454838T3 (en) |
ES (1) | ES2066416T3 (en) |
GR (1) | GR3015276T3 (en) |
IL (1) | IL96242A (en) |
RU (1) | RU2107481C1 (en) |
WO (1) | WO1991007195A1 (en) |
ZA (1) | ZA909225B (en) |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4936825A (en) * | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US4968296A (en) * | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5092837A (en) * | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
US5476445A (en) * | 1990-05-31 | 1995-12-19 | Iovision, Inc. | Glaucoma implant with a temporary flow restricting seal |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5397300A (en) * | 1990-05-31 | 1995-03-14 | Iovision, Inc. | Glaucoma implant |
US6007511A (en) * | 1991-05-08 | 1999-12-28 | Prywes; Arnold S. | Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation |
US5300020A (en) * | 1991-05-31 | 1994-04-05 | Medflex Corporation | Surgically implantable device for glaucoma relief |
US5370607A (en) * | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
WO1994013234A1 (en) * | 1992-12-17 | 1994-06-23 | Michael Andrew Coote | Implant device and method for treatment of glaucoma |
US5342370A (en) * | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
CA2168347A1 (en) | 1993-08-02 | 1995-02-09 | Thomas A. Silvestrini | Segmented preformed intrastromal corneal insert |
FR2710269A1 (en) * | 1993-09-22 | 1995-03-31 | Voir Vivre | Implantable device for the treatment of edemas. |
FR2721499B1 (en) * | 1994-06-22 | 1997-01-03 | Opsia | Trabeculectomy implant. |
US5520631A (en) * | 1994-07-22 | 1996-05-28 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US5704907A (en) * | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US6102045A (en) * | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5433701A (en) * | 1994-12-21 | 1995-07-18 | Rubinstein; Mark H. | Apparatus for reducing ocular pressure |
US5626558A (en) | 1995-05-05 | 1997-05-06 | Suson; John | Adjustable flow rate glaucoma shunt and method of using same |
AU5857396A (en) * | 1995-05-14 | 1996-11-29 | Optonol Ltd. | Intraocular implant, delivery device, and method of implanta tion |
US5968058A (en) * | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
IL113723A (en) * | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
AUPO394496A0 (en) * | 1996-11-29 | 1997-01-02 | Lions Eye Institute | Biological microfistula tube and implantation method and apparatus |
FR2759576B1 (en) * | 1997-02-17 | 1999-08-06 | Corneal Ind | PRE-DESCEMETIC SCLERO-KERATECTOMY IMPLANT |
FR2759577B1 (en) * | 1997-02-17 | 1999-08-06 | Corneal Ind | DEEP SCLERECTOMY IMPLANT |
US5882327A (en) * | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
US6050970A (en) * | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
US6007578A (en) | 1997-10-08 | 1999-12-28 | Ras Holding Corp | Scleral prosthesis for treatment of presbyopia and other eye disorders |
US6991650B2 (en) | 1997-10-08 | 2006-01-31 | Refocus Ocular, Inc. | Scleral expansion device having duck bill |
US6203513B1 (en) | 1997-11-20 | 2001-03-20 | Optonol Ltd. | Flow regulating implant, method of manufacture, and delivery device |
US8313454B2 (en) * | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
RU2160574C1 (en) * | 1999-03-23 | 2000-12-20 | Козлова Татьяна Валентиновна | Method and device for treating the cases of glaucoma |
CZ20013823A3 (en) | 1999-04-26 | 2002-03-13 | Gmp Vision Solutions, Inc. | Stent device and method for treating glaucoma |
US20050119601A9 (en) * | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US6558342B1 (en) | 1999-06-02 | 2003-05-06 | Optonol Ltd. | Flow control device, introducer and method of implanting |
US7008396B1 (en) | 1999-09-03 | 2006-03-07 | Restorvision, Inc. | Ophthalmic device and method of manufacture and use |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US6533768B1 (en) * | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
CN2421967Y (en) * | 2000-05-26 | 2001-03-07 | 杨若愚 | Artificial trabecular support |
DE10042310A1 (en) | 2000-08-29 | 2002-03-14 | Aixmed Ges Fuer Medizintechnik | Aqueous humor drainage device |
WO2002021965A1 (en) | 2000-09-12 | 2002-03-21 | Anamed, Inc. | System for packaging and handling an implant and method of use |
US8668735B2 (en) | 2000-09-12 | 2014-03-11 | Revision Optics, Inc. | Corneal implant storage and delivery devices |
US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
CA2683224C (en) | 2001-04-07 | 2014-12-02 | Glaukos Corporation | System and methods thereof for treatment of ocular disorders |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
US7488303B1 (en) | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
WO2002089699A2 (en) | 2001-05-03 | 2002-11-14 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US20060241750A1 (en) * | 2001-05-22 | 2006-10-26 | Ras Holding Corp | Scleral expansion device having duck bill |
EP1418864A4 (en) * | 2001-08-03 | 2009-07-01 | Research Technologies Glaucoma | Method and intra sclera implant for treatment of glaucoma and presbyopia |
US8267995B2 (en) * | 2001-08-03 | 2012-09-18 | David Castillejos | Method and intra sclera implant for treatment of glaucoma and presbyopia |
BR0211969A (en) | 2001-08-16 | 2006-11-07 | Gmp Vision Solutions Inc | improved bypass device and its deployment method |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
GB0121168D0 (en) * | 2001-08-31 | 2001-10-24 | Duckworth & Kent Ltd | Ophthalmic devices and procedures |
US20030097151A1 (en) * | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
US7163543B2 (en) * | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
AU2003256657A1 (en) * | 2002-07-19 | 2004-02-09 | Yale University | Uveoscleral drainage device |
US20070027537A1 (en) * | 2002-08-02 | 2007-02-01 | David Castillejos | Method and intra-sclera implant for treatment of glaucoma and presbyopia |
US7160264B2 (en) * | 2002-12-19 | 2007-01-09 | Medtronic-Xomed, Inc. | Article and method for ocular aqueous drainage |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
JP2007526013A (en) * | 2003-06-16 | 2007-09-13 | ソルクス インコーポレイテッド | Shunt device for treating glaucoma |
AU2003274907A1 (en) * | 2003-07-31 | 2005-03-07 | David L. Matlock | Speculum for colpoplasty |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US8900296B2 (en) | 2007-04-20 | 2014-12-02 | Revision Optics, Inc. | Corneal inlay design and methods of correcting vision |
US8057541B2 (en) | 2006-02-24 | 2011-11-15 | Revision Optics, Inc. | Method of using small diameter intracorneal inlays to treat visual impairment |
US10835371B2 (en) | 2004-04-30 | 2020-11-17 | Rvo 2.0, Inc. | Small diameter corneal inlay methods |
US7776086B2 (en) | 2004-04-30 | 2010-08-17 | Revision Optics, Inc. | Aspherical corneal implant |
US7862531B2 (en) * | 2004-06-25 | 2011-01-04 | Optonol Ltd. | Flow regulating implants |
US20060116759A1 (en) * | 2004-11-30 | 2006-06-01 | Thornton Spencer P | Method of treating presbyopia and other eye conditions |
WO2007035356A2 (en) * | 2005-09-16 | 2007-03-29 | Bg Implant, Inc. | Glaucoma treatment devices and methods |
CN100415190C (en) * | 2005-10-17 | 2008-09-03 | 西安交通大学 | Novel aqueous humor drainage device for glaucoma |
US20070106200A1 (en) * | 2005-11-08 | 2007-05-10 | Brian Levy | Intraocular shunt device and method |
ES2653845T3 (en) | 2006-01-17 | 2018-02-09 | Novartis Ag | Drug administration treatment device |
ES2551782T3 (en) | 2006-01-17 | 2015-11-23 | Transcend Medical, Inc. | Device for the treatment of glaucoma |
US10555805B2 (en) | 2006-02-24 | 2020-02-11 | Rvo 2.0, Inc. | Anterior corneal shapes and methods of providing the shapes |
US20070293807A1 (en) * | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
WO2008005873A2 (en) * | 2006-06-30 | 2008-01-10 | Aquesys Inc. | Methods, systems and apparatus for relieving pressure in an organ |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
AU2007272963B2 (en) | 2006-07-11 | 2013-05-23 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
EP2088976B1 (en) | 2006-11-10 | 2019-07-03 | Glaukos Corporation | Uveoscleral shunt |
US9271828B2 (en) | 2007-03-28 | 2016-03-01 | Revision Optics, Inc. | Corneal implant retaining devices and methods of use |
US9549848B2 (en) | 2007-03-28 | 2017-01-24 | Revision Optics, Inc. | Corneal implant inserters and methods of use |
US8162953B2 (en) | 2007-03-28 | 2012-04-24 | Revision Optics, Inc. | Insertion system for corneal implants |
US20080277332A1 (en) * | 2007-05-11 | 2008-11-13 | Becton, Dickinson And Company | Micromachined membrane filter device for a glaucoma implant and method for making the same |
US20080306429A1 (en) * | 2007-06-07 | 2008-12-11 | Shields Milton B | Uveoscleral drainage device |
EP2173289A4 (en) | 2007-07-17 | 2010-11-24 | Transcend Medical Inc | Ocular implant with hydrogel expansion capabilities |
JP5323073B2 (en) * | 2007-08-02 | 2013-10-23 | リフォーカス グループ、インコーポレイテッド | Scleral prosthesis with a crossbar for treating presbyopia and other eye diseases |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8337509B2 (en) | 2007-11-20 | 2012-12-25 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8109896B2 (en) | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
US9517359B2 (en) | 2009-02-18 | 2016-12-13 | Eye Tech Care | High intensity focused ultrasound device with a concave segment shaped transducer for eye treatment |
EP2092916A1 (en) | 2008-02-19 | 2009-08-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
US8267882B2 (en) | 2008-03-05 | 2012-09-18 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US9539143B2 (en) | 2008-04-04 | 2017-01-10 | Revision Optics, Inc. | Methods of correcting vision |
ES2640867T3 (en) | 2008-06-25 | 2017-11-07 | Novartis Ag | Eye implant with ability to change shape |
US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
ES2786101T3 (en) | 2009-01-28 | 2020-10-08 | Alcon Inc | Ocular implant with qualities of rigidity, methods and implantation system |
CA2756672A1 (en) * | 2009-03-26 | 2010-09-30 | Abbott Medical Optics Inc. | Glaucoma shunts with flow management and improved surgical performance |
US8961600B2 (en) * | 2009-06-25 | 2015-02-24 | Optonol Ltd. | Method of using a fiber matrix for maintaining space in soft tissues |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
CA2766192C (en) | 2009-07-09 | 2017-10-24 | Ivantis, Inc. | Ocular implants for residing partially in schlemm's canal |
CN102647960A (en) | 2009-10-23 | 2012-08-22 | 伊万提斯公司 | Ocular implant system and method |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
WO2011083358A1 (en) | 2010-01-11 | 2011-07-14 | Eye Tech Care | Device for treating an ocular pathology by applying doses of laser energy |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US8469948B2 (en) | 2010-08-23 | 2013-06-25 | Revision Optics, Inc. | Methods and devices for forming corneal channels |
US20160256317A1 (en) | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Methods for implanting intraocular shunts |
US8585629B2 (en) | 2010-11-15 | 2013-11-19 | Aquesys, Inc. | Systems for deploying intraocular shunts |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
WO2013040079A1 (en) | 2011-09-13 | 2013-03-21 | Dose Medical Corporation | Intraocular physiological sensor |
AU2012325705B2 (en) | 2011-10-21 | 2017-07-20 | Revision Optics, Inc. | Corneal implant storage and delivery devices |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
WO2013148275A2 (en) | 2012-03-26 | 2013-10-03 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
WO2013160907A1 (en) * | 2012-04-23 | 2013-10-31 | Ghansham Das Agrawal | A device for treatment of glaucoma |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
EP3228286A1 (en) | 2012-09-17 | 2017-10-11 | Novartis AG | Expanding ocular impant devices |
WO2014078288A1 (en) | 2012-11-14 | 2014-05-22 | Transcend Medical, Inc. | Flow promoting ocular implant |
WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
EP3068354B1 (en) | 2013-11-14 | 2023-06-28 | Aquesys, Inc. | Intraocular shunt inserter |
EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
PE20151266A1 (en) * | 2014-07-01 | 2015-09-10 | Velasquez Mario Eduardo Miranda | DRAINAGE DEVICE FOR THE CONTROL OF INTRAOCULAR PRESSURE IN GLAUCOMA |
WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
US10736778B2 (en) | 2014-12-31 | 2020-08-11 | Microoptx Inc. | Glaucoma treatment devices and methods |
WO2016144404A1 (en) | 2015-03-12 | 2016-09-15 | Revision Optics, Inc. | Methods of correcting vision |
FR3034320B1 (en) | 2015-03-31 | 2017-04-28 | Eye Tech Care | ULTRASOUND TREATMENT OCULAR PROBE |
UA122570C2 (en) | 2015-06-03 | 2020-12-10 | Аквісіс, Інк. | Ab externo intraocular shunt placement |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
CA3000402A1 (en) | 2015-09-30 | 2017-04-06 | Microoptx Inc. | Dry eye treatment devices and methods |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
CA3025526A1 (en) | 2016-06-02 | 2017-12-07 | Aquesys, Inc. | Intraocular drug delivery |
RU175984U1 (en) * | 2017-03-16 | 2017-12-25 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Device for reducing intraocular pressure |
RU176012U1 (en) * | 2017-04-03 | 2017-12-26 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Device for reducing excessive intraocular pressure |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
CN108524096A (en) * | 2018-06-28 | 2018-09-14 | 吴莺 | Aqueous humor drainage device is fixed in a kind of sclera |
US11672701B2 (en) | 2018-10-25 | 2023-06-13 | Amo Groningen B.V. | Bleb control glaucoma shunts |
DE102019216248B3 (en) * | 2019-10-22 | 2020-12-24 | Burkhard Awe | Implant and implant system for avoiding adhesions and / or scarring of a scleral cover created by means of trabeculectomy |
EP4274529A1 (en) | 2021-01-11 | 2023-11-15 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915172A (en) * | 1970-05-27 | 1975-10-28 | Ceskoslovenska Akademie Ved | Capillary drain for glaucoma |
US4037604A (en) * | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4457757A (en) * | 1981-07-20 | 1984-07-03 | Molteno Anthony C B | Device for draining aqueous humour |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4787885A (en) * | 1984-04-06 | 1988-11-29 | Binder Perry S | Hydrogel seton |
US4634418A (en) * | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
NZ215409A (en) * | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4722724A (en) * | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4936825A (en) * | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
-
1989
- 1989-11-17 US US07/437,840 patent/US4946436A/en not_active Ceased
-
1990
- 1990-10-26 CA CA002045178A patent/CA2045178C/en not_active Expired - Fee Related
- 1990-10-26 ES ES91900637T patent/ES2066416T3/en not_active Expired - Lifetime
- 1990-10-26 EP EP91900637A patent/EP0454838B1/en not_active Expired - Lifetime
- 1990-10-26 AT AT91900637T patent/ATE115388T1/en not_active IP Right Cessation
- 1990-10-26 KR KR1019910700757A patent/KR100187526B1/en not_active IP Right Cessation
- 1990-10-26 JP JP3500779A patent/JP3044238B2/en not_active Expired - Lifetime
- 1990-10-26 DE DE69015161T patent/DE69015161T2/en not_active Expired - Fee Related
- 1990-10-26 WO PCT/US1990/006216 patent/WO1991007195A1/en active IP Right Grant
- 1990-10-26 RU SU5001487A patent/RU2107481C1/en active
- 1990-10-26 DK DK91900637.9T patent/DK0454838T3/en active
- 1990-11-05 IL IL9624290A patent/IL96242A/en not_active IP Right Cessation
- 1990-11-16 CN CN90109295A patent/CN1026754C/en not_active Expired - Fee Related
- 1990-11-16 ZA ZA909225A patent/ZA909225B/en unknown
-
1995
- 1995-03-03 GR GR940404176T patent/GR3015276T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0454838A1 (en) | 1991-11-06 |
ES2066416T3 (en) | 1995-03-01 |
KR920700710A (en) | 1992-08-10 |
CA2045178A1 (en) | 1991-05-18 |
ATE115388T1 (en) | 1994-12-15 |
CN1026754C (en) | 1994-11-30 |
ZA909225B (en) | 1991-09-25 |
DE69015161D1 (en) | 1995-01-26 |
IL96242A0 (en) | 1991-08-16 |
DE69015161T2 (en) | 1995-05-11 |
JP3044238B2 (en) | 2000-05-22 |
DK0454838T3 (en) | 1995-05-15 |
AU7786691A (en) | 1991-06-13 |
EP0454838A4 (en) | 1992-03-18 |
GR3015276T3 (en) | 1995-06-30 |
JPH04503767A (en) | 1992-07-09 |
WO1991007195A1 (en) | 1991-05-30 |
RU2107481C1 (en) | 1998-03-27 |
IL96242A (en) | 1996-10-31 |
AU642498B2 (en) | 1993-10-21 |
KR100187526B1 (en) | 1999-06-01 |
US4946436A (en) | 1990-08-07 |
EP0454838B1 (en) | 1994-12-14 |
CN1052253A (en) | 1991-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2045178C (en) | Pressure-relieving device and process for implanting | |
USRE35390E (en) | Pressure relieving device and process for implanting | |
US4604087A (en) | Aqueous humor drainage device | |
US4634418A (en) | Hydrogel seton | |
US4787885A (en) | Hydrogel seton | |
US5743868A (en) | Corneal pressure-regulating implant device | |
JP3088746B2 (en) | Glaucoma implant | |
CA1295907C (en) | Glaucoma drainage in the lacrimal system | |
EP0773759B1 (en) | Glaucoma implant with a temporary flow-restricting seal | |
JP3670291B2 (en) | Intraocular implant, introduction device | |
US4886488A (en) | Glaucoma drainage the lacrimal system and method | |
US4402681A (en) | Artificial implant valve for the regulation of intraocular pressure | |
US6050970A (en) | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye | |
US5520631A (en) | Method and apparatus for lowering the intraocular pressure of an eye | |
KR100778908B1 (en) | Systems and methods for reducing intraocular pressure | |
US20030236483A1 (en) | Dual drainage ocular shunt for glaucoma | |
EP0168201B1 (en) | Aqueous humour drainage device | |
RU2749066C2 (en) | Apparatus and method of extracting aqueous humour | |
JP2007526013A (en) | Shunt device for treating glaucoma | |
US20050267397A1 (en) | Aqueous drainage and flow regulating implant | |
AU642498C (en) | Pressure-relieving device and process for implanting | |
CA1238833A (en) | Aqueous humor drainage device | |
WO2003049639A9 (en) | Trabeculectomy (guarded filtration procedure) with tissue re-enforcement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |